Serialization and track-and-trace capabilities are not just useful for meeting regulatory compliance mandates; pharmaceutical companies can also explore their use to improve supply chain planning and operations, elevate patient engagement, and increase sales and marketing effectiveness.
The opportunities for the Indian pharmaceutical industry are immense but increasing competition, increasing regulatory pressures and stringent price control means that companies need to constantly improve their costs and service levels. Supply chain efficiencies will play a crucial role going forward and will become the key differentiator for companies. Companies will therefore need to adopt an approach that encompasses strategic, tactical and operational interventions to remain competitive and create value for their customers
The document summarizes the global e-pharmacy market from 2020 to 2027. It discusses key factors like growing revenue potential and comprehensive analysis at international, company, and regional levels. The e-pharmacy market allows for historical and potential future scenario analysis. It also examines competitive landscape and major players in the industry. The report provides an in-depth look at market segmentation, trends, and scope for the e-pharmacy beauty and personal care sector. It concludes with an overview of the e-pharmacy market report scope and contact information for the publisher.
The pharmaceutical value chain involves three main components: manufacturing the drug, distributing it, and dispensing it to patients. Manufacturing includes research and development, clinical trials, regulatory approval, and commercial production. It represents a significant cost, especially for innovative drugs that can take over a decade to develop. Generic manufacturers have lower costs. The value provided includes new medical treatments and wider health and economic benefits. Manufacturers' net prices are often lower than list prices due to discounts negotiated with buyers. The level of discount varies between generic and branded drugs and countries.
This document outlines a vision for next-generation commercial capabilities within the pharmaceutical industry. It discusses the paradigm shift occurring as healthcare markets evolve more rapidly, driving the need for pharmaceutical companies to innovate their commercial models to navigate increasing complexity and costs. It proposes a collaborative model where companies leverage external partners' expertise in analytics, technology, and skills alongside internal assets to build commercial centers of excellence. These centers of excellence would standardize processes while clustering subject matter expertise to develop capabilities as a strategic differentiator and recognize efficiencies over time. The goal is to provide faster access to insights from vast and diverse healthcare data sources to implement locally relevant solutions on a global scale.
Conceptual paper on Study of FMCG & Pharmaceutical Market: Identifying the Di...inventionjournals
With the growing pace of Pharmaceutical market FMCG players are interested to extend their portfolio to tap the market share. Although strict regulatory norms and medico knowledge is the hindrance in their path. On the other hand strong supply chain network of FMCG Industry makes the things easy for them and on which pharmaceutical players are having keen eye. Under this environment both Industrialist and academicians are interested to explore the crossroads where both FMCG and Pharmaceutical Market intercepts. This manuscript is intended to explore that area and study the possible similarities and differences in both the markets so that effective business models could be developed.Work is primarily based on secondary data collected through various reports, journals, e-papers and online repositories. For the sake of avoiding any obsolete data articles has been considered since 2006-2016 only (last 10 years). Comparative analysis has been made on the selected postulates after critical thinking. Appropriate conclusion has been drawn which has relevant implications for FMCG & Pharma players, Policy makers, Management students, Researchers in the concerned areas and the related Entrepreneurs
This document discusses logistics and supply chain issues in the pharmaceutical industry. It notes that the pharmaceutical market is growing significantly and R&D spending is over $100 billion annually. Proper supply chain management can yield large cost reductions and improvements in key metrics. Some key issues include maintaining temperature control of perishable drugs, crisis management for epidemics, incentives for reducing inventory, counterfeiting, outdated manufacturing sites, and the complex network design needed to control vast product portfolios globally. Logistics has become increasingly important as it represents a larger portion of total costs, and innovative technologies may help address some of these challenges.
Transforming Pharmaceutical Operational Performance with Supply Chain Traceab...SupplyScape
This document discusses how track and trace technologies can transform pharmaceutical business performance by enabling supply chain as a strategic asset. It provides an overview of trends driving increased focus on supply chains, describes implications of track and trace on supply chain operations and security. The document also presents two case studies, one on a global pharmaceutical manufacturer and one on a leading drug store chain, analyzing potential benefits of track and trace technologies across various operational areas like inventory management, out-of-stock reduction, returns management, and more. It concludes by suggesting pharmaceutical companies need to address compliance responsibilities globally and prioritize an implementation plan to leverage investments in track and trace.
Supply Chain Management of Pharmaceuticals CompanyRageeb Hasan
This document analyzes the supply chain management of Eskayef Pharmaceuticals Ltd., a leading pharmaceutical company in Bangladesh. It begins with an executive summary that outlines the objectives of studying Eskayef's supply chain and how it is managed. The document then provides background on Eskayef and states the research questions. It describes the methodology used, which included surveys of Eskayef employees, retailers, and customers. The findings suggest that Eskayef faces challenges like lack of coordination and inventory management issues. However, respondents also reported benefits of Eskayef's supply chain like reduced costs and cycle times. In closing, the document notes the importance of effective supply chain management in the pharmaceutical industry.
The opportunities for the Indian pharmaceutical industry are immense but increasing competition, increasing regulatory pressures and stringent price control means that companies need to constantly improve their costs and service levels. Supply chain efficiencies will play a crucial role going forward and will become the key differentiator for companies. Companies will therefore need to adopt an approach that encompasses strategic, tactical and operational interventions to remain competitive and create value for their customers
The document summarizes the global e-pharmacy market from 2020 to 2027. It discusses key factors like growing revenue potential and comprehensive analysis at international, company, and regional levels. The e-pharmacy market allows for historical and potential future scenario analysis. It also examines competitive landscape and major players in the industry. The report provides an in-depth look at market segmentation, trends, and scope for the e-pharmacy beauty and personal care sector. It concludes with an overview of the e-pharmacy market report scope and contact information for the publisher.
The pharmaceutical value chain involves three main components: manufacturing the drug, distributing it, and dispensing it to patients. Manufacturing includes research and development, clinical trials, regulatory approval, and commercial production. It represents a significant cost, especially for innovative drugs that can take over a decade to develop. Generic manufacturers have lower costs. The value provided includes new medical treatments and wider health and economic benefits. Manufacturers' net prices are often lower than list prices due to discounts negotiated with buyers. The level of discount varies between generic and branded drugs and countries.
This document outlines a vision for next-generation commercial capabilities within the pharmaceutical industry. It discusses the paradigm shift occurring as healthcare markets evolve more rapidly, driving the need for pharmaceutical companies to innovate their commercial models to navigate increasing complexity and costs. It proposes a collaborative model where companies leverage external partners' expertise in analytics, technology, and skills alongside internal assets to build commercial centers of excellence. These centers of excellence would standardize processes while clustering subject matter expertise to develop capabilities as a strategic differentiator and recognize efficiencies over time. The goal is to provide faster access to insights from vast and diverse healthcare data sources to implement locally relevant solutions on a global scale.
Conceptual paper on Study of FMCG & Pharmaceutical Market: Identifying the Di...inventionjournals
With the growing pace of Pharmaceutical market FMCG players are interested to extend their portfolio to tap the market share. Although strict regulatory norms and medico knowledge is the hindrance in their path. On the other hand strong supply chain network of FMCG Industry makes the things easy for them and on which pharmaceutical players are having keen eye. Under this environment both Industrialist and academicians are interested to explore the crossroads where both FMCG and Pharmaceutical Market intercepts. This manuscript is intended to explore that area and study the possible similarities and differences in both the markets so that effective business models could be developed.Work is primarily based on secondary data collected through various reports, journals, e-papers and online repositories. For the sake of avoiding any obsolete data articles has been considered since 2006-2016 only (last 10 years). Comparative analysis has been made on the selected postulates after critical thinking. Appropriate conclusion has been drawn which has relevant implications for FMCG & Pharma players, Policy makers, Management students, Researchers in the concerned areas and the related Entrepreneurs
This document discusses logistics and supply chain issues in the pharmaceutical industry. It notes that the pharmaceutical market is growing significantly and R&D spending is over $100 billion annually. Proper supply chain management can yield large cost reductions and improvements in key metrics. Some key issues include maintaining temperature control of perishable drugs, crisis management for epidemics, incentives for reducing inventory, counterfeiting, outdated manufacturing sites, and the complex network design needed to control vast product portfolios globally. Logistics has become increasingly important as it represents a larger portion of total costs, and innovative technologies may help address some of these challenges.
Transforming Pharmaceutical Operational Performance with Supply Chain Traceab...SupplyScape
This document discusses how track and trace technologies can transform pharmaceutical business performance by enabling supply chain as a strategic asset. It provides an overview of trends driving increased focus on supply chains, describes implications of track and trace on supply chain operations and security. The document also presents two case studies, one on a global pharmaceutical manufacturer and one on a leading drug store chain, analyzing potential benefits of track and trace technologies across various operational areas like inventory management, out-of-stock reduction, returns management, and more. It concludes by suggesting pharmaceutical companies need to address compliance responsibilities globally and prioritize an implementation plan to leverage investments in track and trace.
Supply Chain Management of Pharmaceuticals CompanyRageeb Hasan
This document analyzes the supply chain management of Eskayef Pharmaceuticals Ltd., a leading pharmaceutical company in Bangladesh. It begins with an executive summary that outlines the objectives of studying Eskayef's supply chain and how it is managed. The document then provides background on Eskayef and states the research questions. It describes the methodology used, which included surveys of Eskayef employees, retailers, and customers. The findings suggest that Eskayef faces challenges like lack of coordination and inventory management issues. However, respondents also reported benefits of Eskayef's supply chain like reduced costs and cycle times. In closing, the document notes the importance of effective supply chain management in the pharmaceutical industry.
The document summarizes a report on the perspectives of pharmaceutical, healthcare, and medical device supply chain executives. It highlights their key supply chain priorities for the year and biggest upcoming challenges. The report profiles respondents from various industries and geographic regions. It also examines the respondents' biggest supply chain priorities and obstacles, as well as their use of contract manufacturing, technology, and third-party logistics partners.
The United States might out-perform the IVD markets of many other nations in growth as well as size. Yet there are challenges. Will ACA-based changes be shortlived? This White Paper discusses them. Based on information from our United States IVD Market.
United States life sciences companies face numerous challenges in 2015 related to market changes, consolidation, pricing pressures, and health reform. Six key issues are highlighted: 1) Market reconfiguration and consolidation due to factors like expiring patents are driving the need for companies to reassess strategies and explore M&A opportunities. 2) Pricing pressures exist from government efforts to control costs and from health plans increasing efforts to reduce pharmaceutical costs. 3) Health reform is shifting the market to value-based care, requiring companies to demonstrate drugs' and devices' true value and economic impact compared to alternatives.
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
The document summarizes a report by IMARC Group on the global oncology biosimilars market. It discusses the growth of the market driven by the rising prevalence of cancer and upcoming patent expiries. Oncology biosimilars are similar to original biologics but are more affordable, improving access to treatment. The report analyzes the market by drug type, distribution channel, and region. It also profiles the major players in the industry.
Pfizer is the world's largest pharmaceutical company by revenue. It has over 103,700 employees worldwide and had $67.42 billion in revenue in 2011. In India, Pfizer has over 3,000 employees and a manufacturing facility in Thane, Maharashtra. The pharmaceutical industry is forecast to have 5-8% annual growth to 2015 despite economic challenges. Companies are focusing on supply chain management and cost cutting to drive efficiency. Effective management of transportation, inventory, expiration dates and recalls is important for pharmaceutical supply chains.
The document discusses the supply chain of the pharmaceutical industry. It describes the typical supply chain process including raw material sourcing, manufacturing, distribution and dispensing. It highlights several critical issues in managing pharmaceutical supply chains including maintaining temperature control, complex network design, and focus on research and development. It also discusses risks in pharmaceutical supply chains such as uncertainty in demand and the product development pipeline. Finally, it provides an overview of the current distribution system in India which involves clearing and forwarding agents and stockists.
A Strategic Approach to CMO Serialization ComplianceCognizant
To avoid supply chain disruptions due to regulatory compliance issues, pharmaceuticals companies need to coordinate with all their contract manufacturing organizations (CMOs) on an effective serialization strategy.
The document summarizes the current state and challenges facing India's pharmaceutical supply chain. It finds that while the industry has grown significantly, Indian pharma companies are still lagging best practices in key performance areas like customer service, inventory levels, and supply chain costs. Major challenges include issues with quality and regulatory compliance that are affecting exports and domestic sales, as well as high product proliferation, supply chain fragmentation, and some infrastructure gaps. Addressing these challenges will be important for the industry to sustain growth and gain a competitive advantage.
McKesson Corporation is a leading healthcare company that operates in pharmaceutical distribution and healthcare information technology. The document recommends buying McKesson stock, citing the company's leadership positions in key healthcare markets, stable cash flows, revenue growth, and opportunities from an aging population and international expansion. While healthcare reforms and increasing competition pose risks, the recommendation is based on McKesson's scale advantages in distribution, potential for growth in its technology business, and the overall growth of the defensive healthcare sector.
The consumer health market is undergoing rapid changes as it expands globally. Pharmaceutical companies have traditionally dominated this market but consumer packaged goods companies are increasingly entering it due to attractive growth. Both types of companies need to combine scientific expertise with a focus on consumers and marketing to succeed. Pharmaceutical companies currently have an advantage in regulating environments and product efficacy but need marketing expertise from consumer goods companies. The fight for talent in this evolving market is intense as companies need to attract professionals with diverse skills from both industries to drive innovation and adapt to changing trends.
This presentation by Farasat Bokhari was made at the 2014 Global Forum on Competition (27-28 February) at the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforum
Supply chain issues in Pharma industryJaimeen Rana
This document discusses issues in the pharmaceutical supply chain. It outlines the life cycle of a pharmaceutical product from research to commercial manufacturing. It then describes the various components in the manufacturing and distribution chain from primary manufacturing to retailers. It notes challenges like the bullwhip effect, need to hold large active ingredient stocks, and lack of visibility beyond the first customer. Finally, it proposes steps to improve supply chain performance through increased visibility, reducing working capital, and ensuring efficiencies benefit all parties.
This presentation by Pradeep Mehta was made at the 2014 Global Forum on Competition (27-28 February) during the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforum
This document analyzes and dispels five common myths about the drug delivery industry. It argues that drug delivery has delivered many new products, the market is growing not declining, the business model can be sustainable, product line extensions using drug delivery approaches are effective strategies, and drug delivery companies offer diverse technologies, not just similar controlled release solutions. The drug delivery industry plays a key role in addressing challenges in pharma by developing improved treatment options.
This document summarizes analysis of unpartnered pharmaceutical products from Medtrack in September 2015. It finds that opportunities remain abundant, with many preclinical and early-stage candidates in private company pipelines as well as late-stage candidates in public company pipelines. Oncology remains the leading therapeutic area for unpartnered drugs. Several private and public companies are highlighted that have significant unpartnered pipelines that could be candidates for partnership or acquisition deals. The document analyzes Phase III candidates in more detail and finds some oncology drugs that have above average likelihood of approval based on proprietary modeling.
LogiQuest Season 2 - Challenges and Opportunities for Organized 3PL in Pharma...Mahindra Logistics
The team came up with a well-researched presentation that demonstrated the challenges and opportunities for organized 3PL in Supply Chain. The team, Dark Horses from NITIE, won the LogiQuest Season 2.
This document summarizes a study on supply chain practices in the pharmaceutical industry. It finds that the pharmaceutical supply chain is very fragmented, complex, and global. It operates in a competitive environment while also needing to ensure high regulations for patient safety. An effective supply chain can reduce costs and increase efficiency. However, it also faces risks like counterfeiting and needs strong risk management practices. The document outlines Pfizer's successful risk management efforts and FoxMeyer Drug Company's risk management failure which led to bankruptcy. Overall, the pharmaceutical supply chain is highly complex and regulated, with high costs of success or failure.
The hospital segment in India is becoming increasingly attractive for pharmaceutical companies due to its large size, fast growth rate, and investment opportunities. However, pharmaceutical companies will need to rethink their business strategies to succeed in this evolving market. Hospitals are exerting more control over physician prescriptions and purchasing decisions. Additionally, the relationship between physicians and hospitals is shifting, with hospitals gaining more influence. To effectively engage with the hospital segment, pharmaceutical companies will need to tailor their strategies, products, targeting, and metrics to the unique dynamics of each hospital type.
En la siguiente diapositiva podremos demostrar y explicar un poco de lo que son los valores y su definición, que son, cuales son, su importancia, y de como podemos aplicarlos y de estos obtener buenos resultados, como por ejemplo, una mejor mejorar el rendimiento de aptitud de la sociedad.
Phen375 pros and cons : A detailed reviewRoss Cooper
Phen375 is a natural weight supplement. It is an efficient and safe way to lose weight. It is totally safe to use and has no side effects.
Get Your Phen375 here :- http://www.phwins.com
The document summarizes a report on the perspectives of pharmaceutical, healthcare, and medical device supply chain executives. It highlights their key supply chain priorities for the year and biggest upcoming challenges. The report profiles respondents from various industries and geographic regions. It also examines the respondents' biggest supply chain priorities and obstacles, as well as their use of contract manufacturing, technology, and third-party logistics partners.
The United States might out-perform the IVD markets of many other nations in growth as well as size. Yet there are challenges. Will ACA-based changes be shortlived? This White Paper discusses them. Based on information from our United States IVD Market.
United States life sciences companies face numerous challenges in 2015 related to market changes, consolidation, pricing pressures, and health reform. Six key issues are highlighted: 1) Market reconfiguration and consolidation due to factors like expiring patents are driving the need for companies to reassess strategies and explore M&A opportunities. 2) Pricing pressures exist from government efforts to control costs and from health plans increasing efforts to reduce pharmaceutical costs. 3) Health reform is shifting the market to value-based care, requiring companies to demonstrate drugs' and devices' true value and economic impact compared to alternatives.
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
The document summarizes a report by IMARC Group on the global oncology biosimilars market. It discusses the growth of the market driven by the rising prevalence of cancer and upcoming patent expiries. Oncology biosimilars are similar to original biologics but are more affordable, improving access to treatment. The report analyzes the market by drug type, distribution channel, and region. It also profiles the major players in the industry.
Pfizer is the world's largest pharmaceutical company by revenue. It has over 103,700 employees worldwide and had $67.42 billion in revenue in 2011. In India, Pfizer has over 3,000 employees and a manufacturing facility in Thane, Maharashtra. The pharmaceutical industry is forecast to have 5-8% annual growth to 2015 despite economic challenges. Companies are focusing on supply chain management and cost cutting to drive efficiency. Effective management of transportation, inventory, expiration dates and recalls is important for pharmaceutical supply chains.
The document discusses the supply chain of the pharmaceutical industry. It describes the typical supply chain process including raw material sourcing, manufacturing, distribution and dispensing. It highlights several critical issues in managing pharmaceutical supply chains including maintaining temperature control, complex network design, and focus on research and development. It also discusses risks in pharmaceutical supply chains such as uncertainty in demand and the product development pipeline. Finally, it provides an overview of the current distribution system in India which involves clearing and forwarding agents and stockists.
A Strategic Approach to CMO Serialization ComplianceCognizant
To avoid supply chain disruptions due to regulatory compliance issues, pharmaceuticals companies need to coordinate with all their contract manufacturing organizations (CMOs) on an effective serialization strategy.
The document summarizes the current state and challenges facing India's pharmaceutical supply chain. It finds that while the industry has grown significantly, Indian pharma companies are still lagging best practices in key performance areas like customer service, inventory levels, and supply chain costs. Major challenges include issues with quality and regulatory compliance that are affecting exports and domestic sales, as well as high product proliferation, supply chain fragmentation, and some infrastructure gaps. Addressing these challenges will be important for the industry to sustain growth and gain a competitive advantage.
McKesson Corporation is a leading healthcare company that operates in pharmaceutical distribution and healthcare information technology. The document recommends buying McKesson stock, citing the company's leadership positions in key healthcare markets, stable cash flows, revenue growth, and opportunities from an aging population and international expansion. While healthcare reforms and increasing competition pose risks, the recommendation is based on McKesson's scale advantages in distribution, potential for growth in its technology business, and the overall growth of the defensive healthcare sector.
The consumer health market is undergoing rapid changes as it expands globally. Pharmaceutical companies have traditionally dominated this market but consumer packaged goods companies are increasingly entering it due to attractive growth. Both types of companies need to combine scientific expertise with a focus on consumers and marketing to succeed. Pharmaceutical companies currently have an advantage in regulating environments and product efficacy but need marketing expertise from consumer goods companies. The fight for talent in this evolving market is intense as companies need to attract professionals with diverse skills from both industries to drive innovation and adapt to changing trends.
This presentation by Farasat Bokhari was made at the 2014 Global Forum on Competition (27-28 February) at the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforum
Supply chain issues in Pharma industryJaimeen Rana
This document discusses issues in the pharmaceutical supply chain. It outlines the life cycle of a pharmaceutical product from research to commercial manufacturing. It then describes the various components in the manufacturing and distribution chain from primary manufacturing to retailers. It notes challenges like the bullwhip effect, need to hold large active ingredient stocks, and lack of visibility beyond the first customer. Finally, it proposes steps to improve supply chain performance through increased visibility, reducing working capital, and ensuring efficiencies benefit all parties.
This presentation by Pradeep Mehta was made at the 2014 Global Forum on Competition (27-28 February) during the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforum
This document analyzes and dispels five common myths about the drug delivery industry. It argues that drug delivery has delivered many new products, the market is growing not declining, the business model can be sustainable, product line extensions using drug delivery approaches are effective strategies, and drug delivery companies offer diverse technologies, not just similar controlled release solutions. The drug delivery industry plays a key role in addressing challenges in pharma by developing improved treatment options.
This document summarizes analysis of unpartnered pharmaceutical products from Medtrack in September 2015. It finds that opportunities remain abundant, with many preclinical and early-stage candidates in private company pipelines as well as late-stage candidates in public company pipelines. Oncology remains the leading therapeutic area for unpartnered drugs. Several private and public companies are highlighted that have significant unpartnered pipelines that could be candidates for partnership or acquisition deals. The document analyzes Phase III candidates in more detail and finds some oncology drugs that have above average likelihood of approval based on proprietary modeling.
LogiQuest Season 2 - Challenges and Opportunities for Organized 3PL in Pharma...Mahindra Logistics
The team came up with a well-researched presentation that demonstrated the challenges and opportunities for organized 3PL in Supply Chain. The team, Dark Horses from NITIE, won the LogiQuest Season 2.
This document summarizes a study on supply chain practices in the pharmaceutical industry. It finds that the pharmaceutical supply chain is very fragmented, complex, and global. It operates in a competitive environment while also needing to ensure high regulations for patient safety. An effective supply chain can reduce costs and increase efficiency. However, it also faces risks like counterfeiting and needs strong risk management practices. The document outlines Pfizer's successful risk management efforts and FoxMeyer Drug Company's risk management failure which led to bankruptcy. Overall, the pharmaceutical supply chain is highly complex and regulated, with high costs of success or failure.
The hospital segment in India is becoming increasingly attractive for pharmaceutical companies due to its large size, fast growth rate, and investment opportunities. However, pharmaceutical companies will need to rethink their business strategies to succeed in this evolving market. Hospitals are exerting more control over physician prescriptions and purchasing decisions. Additionally, the relationship between physicians and hospitals is shifting, with hospitals gaining more influence. To effectively engage with the hospital segment, pharmaceutical companies will need to tailor their strategies, products, targeting, and metrics to the unique dynamics of each hospital type.
En la siguiente diapositiva podremos demostrar y explicar un poco de lo que son los valores y su definición, que son, cuales son, su importancia, y de como podemos aplicarlos y de estos obtener buenos resultados, como por ejemplo, una mejor mejorar el rendimiento de aptitud de la sociedad.
Phen375 pros and cons : A detailed reviewRoss Cooper
Phen375 is a natural weight supplement. It is an efficient and safe way to lose weight. It is totally safe to use and has no side effects.
Get Your Phen375 here :- http://www.phwins.com
OneConfig Case study: Amnesty InternationalDave Blythe
High-profile not-for-profit takes control of national Juniper network by deploying OneConfig cloud platform - solves skills and visibility issues in one hit!
El documento habla sobre la ministración de Jesús a las necesidades de la comunidad. Explica que Jesús sanaba enfermedades y dolencias mientras predicaba el evangelio, siguiendo el ejemplo de Dios de ayudar a los necesitados. También cita pasajes bíblicos que instan a los cristianos a alimentar a los hambrientos y vestir a los desnudos, atendiendo las necesidades de la gente como hizo Jesús. Finalmente, da consejos sobre evaluar las verdaderas necesidades de la comunidad local y usar los don
This document lists 101 potential legal situations that individuals may encounter in their daily lives. It suggests that by using LegalShield, individuals will have access to a law firm prepared to assist with any covered personal legal matters that may arise, from wills and estates to family law, criminal charges, consumer protection, real estate, and more, available even around the clock for emergencies. LegalShield aims to make legal assistance more accessible and affordable for common legal issues people face.
The document outlines key provisions from the Rome Statute that established the International Criminal Court (ICC). It discusses the ICC's jurisdiction over genocide, crimes against humanity, and war crimes. It defines these crimes and sets out conditions for the Court's jurisdiction. The ICC has jurisdiction over natural persons and aims to complement national criminal jurisdictions. Its jurisdiction is limited to the most serious crimes of concern to the international community.
Este documento ofrece varias citas bíblicas que alientan a las personas a depositar sus preocupaciones y cargas en Dios, prometiendo que Él los aliviará, sostendrá y cuidará de ellos.
El documento proporciona información sobre los componentes y sistemas básicos de un automóvil, incluyendo el motor, transmisión, frenos, batería, arranque, encendido, carga, alimentación, lubricación, refrigeración, suspensión, dirección y mantenimiento. También describe los implementos de seguridad requeridos y algunas fallas mecánicas comunes.
This document summarizes a panel discussion on making interprofessional simulation education work. The panel consisted of experts from various universities and medical centers. Each panelist discussed common challenges to developing interprofessional education programs and proposed solutions. Some key challenges mentioned included getting buy-in from leadership and learners, issues with scheduling and logistics, and integrating interprofessional education into existing curricula. Proposed solutions focused on involving all stakeholders early, capitalizing on identified needs, and starting with small successes to build support over time. The panel provided insights on implementing successful interprofessional simulation programs in different contexts and settings.
El documento propone estándares para la web que incluyen elementos estructurales como <HEADER>, <NAV>, <SECTION>, <ARTICLE> y <ASIDE> para proveer una estructura útil y atractiva. También provee dinamismo y aplicaciones funcionales a través de compatibilidad, etiquetas como <!DOCTYPE> y <html> que permiten validación nativa sin necesidad de scripts, y tipos específicos en campos de formularios y canvas autofocus.
La energía solar se produce a partir de la luz y el calor del sol, y puede convertirse en energía útil para calentar o generar electricidad. Sus beneficios incluyen ventajas medioambientales, económicas y sociales, así como beneficios educativos.
Este documento es una reflexión del autor sobre su relación con Dios. En múltiples oraciones, el autor describe cómo Dios se ha revelado de diversas maneras a la humanidad (como el camino, la verdad, la vida, etc.), pero la gente a menudo no lo reconoce, no le cree o no lo sigue. El autor también lamenta cómo la gente a veces maldice, desprecia o se rebela contra Dios a pesar de todo lo que Él ha hecho por la humanidad.
Estructura de Archivos
Busqueda y clásificación externa
Búsqueda binaria
Ordenamiento en memoria
Ordenamiento por llaves
Ordenamiento Shell
Registros fijos
Indización y operaciones
Slides from our 04 Feb 2016 Meetup.
http://www.meetup.com/FW-Dev/events/228176322/
An overview of the automotive CAN Bus, On Board Diagnostics (OBD), Tire Pressure Monitoring System (TPMS) and how car companies can cheat on emissions testing. We'll also do a demonstration of how to interface an Arduino to a car using a cheap CAN bus controller
This document outlines 3 steps to becoming mega-leaders: 1) Follow Jesus closely instead of from a safe distance, 2) Become consumed with Jesus' mission of liberating souls through service and sacrifice, and 3) Follow Jesus' model of servant leadership by being humble, compassionate, and living to improve others' lives through service rather than seeking rewards. The passage discusses Jesus leading the disciples on a journey to teach them about discipleship through encounters with blind men and ambitious disciples.
Este documento presenta un libro sobre electrónica digital dirigido a lectores principiantes. El autor explica que su objetivo es hacer el contenido lo más didáctico y práctico posible basándose en escritos de lectores, monografías de estudiantes y programas de simulación. El libro incluye varios capítulos que cubren temas como compuertas lógicas, familias de circuitos integrados digitales y prácticas con circuitos digitales usando placas de entrenamiento. Adicionalmente, se proporcionan enl
The document discusses store layout, design, and visual merchandising. It describes different types of store layouts including grid, racetrack, and free-form layouts. It also discusses elements of store atmosphere and design objectives. Key considerations for store layout include allocation of floor space, area mix, merchandise type and density, and prime locations for merchandise placement.
Pharmaceutical Supply Chains Require New Operational and Technology Models to...Cognizant
The pharmaceutical supply chain requires new operational and technology models to enable collaboration and efficiency. Pharmaceutical companies face slowed growth, industry pressures, and declining margins. They must embrace demand-chain thinking and cloud solutions to share real-time data with partners. This will help manage unpredictable demand, gain inventory visibility, and serve diverse markets. Cloud platforms can provide a common space for stakeholders to connect and share data, fostering transparency and accountability.
McKinsey Sağlık Tedarik Zinciriyle, FMCG Tedarik Zinciri karşılaştırıyor. Sağlık Tedarik Zincirindeki iyileştirme fırsatına ve toplumsal boyutuna dikkat çekiyor.
Endüstri Mühendisliği - Yöneylem teknikleriyle Sağlık Tedarik Zinciri Modellemesidir. Maalesef dünya bu yöntemleri taşıyacak kadar deterministik değildir. Zaten sonraki aşamada fiili model denemesi planlanmış.
Supply Chain Metrics That Matter: A Focus on the Pharmaceutical Industry - 3 ...Lora Cecere
This document provides an analysis of supply chain metrics in the pharmaceutical industry based on financial data from 2000-2011. It finds that while the industry has historically had high gross margins, allowing less focus on supply chain efficiency, changes in the operating environment now require improved supply chain capabilities. Specifically, it examines resiliency levels, effectiveness of R&D spending, impacts of mergers and acquisitions, and cash-to-cash cycle management. The analysis finds room for most pharmaceutical companies to improve supply chain maturity compared to leaders in other industries.
Enterprise Labeling for the Pharmaceutical IndustryLoftware
For the pharmaceutical industry, the focus is on patient safety and improved patient outcomes. It’s also on driving greater efficiencies, cost reductions, and collaboration with contract manufacturers throughout the supply chain. In this environment, labeling is growing in importance, and there are a number of reasons why.
The healthcare supply chain faces increasing pressures from growing complexity, global demand, and quality issues. The current supply chain model will not be able to meet these challenges. Developing new capabilities around segmentation, agility, measurement, alignment and collaboration can help transform supply chain performance. This would lower costs, improve access to healthcare, and enhance patient safety, while also providing strategic benefits to companies. Transforming healthcare supply chains requires an integrated, cross-functional effort.
The document proposes a blockchain-based drug supply chain supervision system to address issues like counterfeiting by allowing all stakeholders like suppliers, manufacturers, transporters, wholesalers, distributors and pharmacies to trace drugs from origin to consumer through an immutable record of transactions. Key components of the proposed system include smart contracts, a Goerli test network and tools like Truffle, Metamask, Solidity and Web3.js to develop a decentralized application that can track drugs and authenticate participants in the supply chain.
Clinical trial supply and logistics involves planning, packaging, distribution, and management of clinical supplies for drug and medical device trials in accordance with regulatory standards. The global market for clinical trial supply and logistics was valued at $14.95 billion in 2017 and is expected to grow at a CAGR of 7.1% through 2026. Key regions include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with Asia Pacific and Latin America expected to experience the fastest growth. Challenges in clinical trial supply management include inaccurate forecasting, cross-vendor alignment issues, and logistical difficulties associated with operating across multiple countries and languages.
The Drug Quality and Security Act grants the FDA more authority to regulate compounded drugs in response to a 2012 meningitis outbreak. The Act requires serialization of drug products, with serial numbers encoded in 2D barcodes by certain deadlines. This increases tracking of drugs throughout the supply chain. SAP Advanced Track and Trace for Pharmaceuticals provides a single platform to manage serial numbers, integrate serialization into business processes, simplify regulatory reporting to different countries, and scale to handle increasing serialization data volumes.
Computerized Physician Order Entry Systems Market.pdfKumar Satyam
The realm of healthcare has undergone a significant transformation with the advent of digital technologies, and one such innovation making waves is the Computerized Physician Order Entry (CPOE) system. According to the latest report by TechSci Research titled "Computerized Physician Order Entry Systems Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028", the Global Computerized Physician Order Entry Systems Market witnessed a valuation of USD 1.65 billion in 2022, with a projected Compound Annual Growth Rate (CAGR) of 6.22% during the forecast period from 2024 to 2028. This comprehensive report provides valuable insights into market dynamics, drivers, trends, and key segments, offering a holistic view for stakeholders and industry participants.
Medical devices equipped for the futureBrand Acumen
The document discusses disruptive changes underway in the medical devices industry that will transform it over the next 5 years. It identifies 5 major disruptors: 1) a power shift to payers and providers who are focusing more on cost and value-based evidence, 2) heightened regulatory scrutiny that is increasing compliance costs, 3) unclear sources of innovation as R&D spending yields diminishing returns, 4) new healthcare delivery models that are shifting care settings out of hospitals, and 5) a need to serve lower socioeconomic classes in developing markets. The disruptors threaten $34 billion in industry profits by 2020 but taking appropriate measures could help maintain revenue growth and offset margin declines, preserving significant value for medical device companies.
Historically, the medical device industry has been highly attractive and relatively stable. As a consequence, established players have been able to compete successfully across the device spectrum, applying common business models and processes without much need for differentiation.
The future, however, is very different as disruptive change is underway. Companies will need to look at new segments and offer end-to-end solutions to secure additional revenue and maintain their profit margins.
This document discusses managing the extended research and development (R&D) supply chain for clinical trials. It presents challenges at different stages of the supply chain from active pharmaceutical ingredient (API) manufacturing through investigational medicinal product (IMP) delivery. Key challenges include forecasting and planning given variable patient enrollment, ensuring visibility and integration across outsourced manufacturing steps, translating complex packaging needs from protocols, and managing drug distribution globally. The article presents different models for R&D supply chains, including fully outsourcing the physical chain or adopting a more patient-oriented model.
Global product serialization is well underway and many companies are not adequately prepared for it. The significant capital costs and lack of knowledge in successful implementation are keeping them behind.
What Are the Challenges Faced by Medicine Distributors in the Industry?go4distributors
Medicine distributors must navigate a complex landscape of regulatory requirements that vary from country to country and even within regions of the same country. Compliance with the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in Europe, and similar regulatory bodies worldwide involves meticulous documentation, regular audits, and adherence to Good Distribution Practices (GDP). These regulations are essential to ensure the safety and efficacy of pharmaceuticals, but they also add a significant burden to distributors. Non-compliance can result in severe penalties, product recalls, and loss of business licenses, making it a critical challenge for distributors.
Drug counterfeiting is a significant public health threat and is rapidly increasing with dozens of new cases being reported throughout the world every day. In the past few months, various
news has been reported in media referring the ongoing activities of counterfeiters making fake and sub-standard medicines in
different parts of India. The article is on need of anti-counterfeit secured packaging solutions like tamper evident and serialization.
As a very critical industry for the health and well-being of people all over the world, the global food industry is subject to a vast amount of regulations throughout the global supply chain. With ongoing technical progress in automation and data processing, regulations will not only continue to grow, but will also demand more and more input from all participants in the supply chain. To achieve compliance with growing global regulations, it will become necessary
to provide fully traceable evidence about all supply chain movements from raw materials to the finished product. Looking beyond regulations, having full transparency and control over your supply chain can also result in fundamental advantages over the competition. If the available data is used properly, it can be harnessed and leveraged to gain a strategic business advantage including improvements in the overall supply chain procedures and a boost in customer trust and confidence by providing transparency about food origins.
Now is the time to take action and evolve your supply chain strategy...
Now is the time to move beyond simply meeting the minimum expectations of regulatory guidelines and evolve to a more strategic approach to complete supply chain integrity...
Now is the time to keep your company out of the headlines because of a recall or compromised link in your extended supply chain...
Is your company ready to meet today’s challenges?Lidia Gasparotto
Visit us online at:
www.ibm.com/electronics/medicaldevices
Is your company ready to meet today’s challenges?
Ask yourself the following questions:
Are your products linked to clinical information systems? •
Is your supply chain optimized to track inventory, handle complaints and •
recalls and manage assets?
Can you comply efficiently with divergent security and privacy regula- •
tions?
Does your company get new products to market as quickly as your •
competitors?
Are your operations efficient and profitable? •
Does your company’s IT environment facilitate the formation of strategic •
alliances with insurance companies, HMOs, hospital buying groups and
supply chain logistics companies?
Can you reduce your tax liabilities through the use of commissionaires?
IBM has developed and refined the tools you need.
The document discusses business strategies for hospitals, including:
1. Improving the hospital to supplier linkage by addressing inefficiencies in the sourcing, order management, and payment cycles that can save 20% or more across procurement.
2. Enhancing the hospital to customer linkage through initiatives like customer relationship management tools, telemedicine, and knowledge management to improve the patient experience.
3. Implementing technologies like automated point-of-use systems, RFID, and wireless sensor networks to increase visibility, optimize inventory, and streamline operations.
Similar to Serialization: Driving Business Value Beyond Compliance (20)
Using Adaptive Scrum to Tame Process Reverse Engineering in Data Analytics Pr...Cognizant
Organizations rely on analytics to make intelligent decisions and improve business performance, which sometimes requires reproducing business processes from a legacy application to a digital-native state to reduce the functional, technical and operational debts. Adaptive Scrum can reduce the complexity of the reproduction process iteratively as well as provide transparency in data analytics porojects.
Data Modernization: Breaking the AI Vicious Cycle for Superior Decision-makingCognizant
The document discusses how most companies are not fully leveraging artificial intelligence (AI) and data for decision-making. It finds that only 20% of companies are "leaders" in using AI for decisions, while the remaining 80% are stuck in a "vicious cycle" of not understanding AI's potential, having low trust in AI, and limited adoption. Leaders use more sophisticated verification of AI decisions and a wider range of AI technologies beyond chatbots. The document provides recommendations for breaking the vicious cycle, including appointing AI champions, starting with specific high-impact decisions, and institutionalizing continuous learning about AI advances.
It Takes an Ecosystem: How Technology Companies Deliver Exceptional ExperiencesCognizant
Experience is becoming a key strategy for technology companies as they shift to cloud-based subscription models. This requires building an "experience ecosystem" that breaks down silos and involves partners. Building such an ecosystem involves adopting a cross-functional approach to experience, making experience data-driven to generate insights, and creating platforms to enable connected selling between companies and partners.
Intuition is not a mystery but rather a mechanistic process based on accumulated experience. Leading businesses are engineering intuition into their organizations by harnessing machine learning software, massive cloud processing power, huge amounts of data, and design thinking in experiences. This allows them to anticipate and act with speed and insight, improving decision making through data-driven insights and acting as if on intuition.
The Work Ahead: Transportation and Logistics Delivering on the Digital-Physic...Cognizant
The T&L industry appears poised to accelerate its long-overdue modernization drive, as the pandemic spurs an increased need for agility and resilience, according to our study.
Enhancing Desirability: Five Considerations for Winning Digital InitiativesCognizant
To be a modern digital business in the post-COVID era, organizations must be fanatical about the experiences they deliver to an increasingly savvy and expectant user community. Getting there requires a mastery of human-design thinking, compelling user interface and interaction design, and a focus on functional and nonfunctional capabilities that drive business differentiation and results.
The Work Ahead in Manufacturing: Fulfilling the Agility MandateCognizant
Manufacturers are ahead of other industries in IoT deployments but lag in investments in analytics and AI needed to maximize IoT's benefits. While many have IoT pilots, few have implemented machine learning at scale to analyze sensor data and optimize processes. To fully digitize manufacturing, investments in automation, analytics, and AI must increase from the current 5.5% of revenue to over 11% to integrate IT, OT, and PT across the value chain.
The Work Ahead in Higher Education: Repaving the Road for the Employees of To...Cognizant
Higher-ed institutions expect pandemic-driven disruption to continue, especially as hyperconnectivity, analytics and AI drive personalized education models over the lifetime of the learner, according to our recent research.
Engineering the Next-Gen Digital Claims Organisation for Australian General I...Cognizant
The document discusses potential future states for the claims organization of Australian general insurers. It notes that gradual changes like increasing climate volatility, new technologies, and changing customer demographics will reshape the insurance industry and claims processes. Five potential end states for claims organizations are described: 1) traditional claims will demand faster processing; 2) a larger percentage of claims will come from new digital risks; 3) claims processes may become "Uberized" through partnerships; 4) claims organizations will face challenges in risk management propositions; 5) humans and machines will work together to adjudicate claims using large data and computing power. The document argues that insurers must transform claims through digital technologies to concurrently improve customer experience, operational effectiveness, and efficiencies
Profitability in the Direct-to-Consumer Marketplace: A Playbook for Media and...Cognizant
Amid constant change, industry leaders need an upgraded IT infrastructure capable of adapting to audience expectations while proactively anticipating ever-evolving business requirements.
Green Rush: The Economic Imperative for SustainabilityCognizant
Green business is good business, according to our recent research, whether for companies monetizing tech tools used for sustainability or for those that see the impact of these initiatives on business goals.
Policy Administration Modernization: Four Paths for InsurersCognizant
The pivot to digital is fraught with numerous obstacles but with proper planning and execution, legacy carriers can update their core systems and keep pace with the competition, while proactively addressing customer needs.
The Work Ahead in Utilities: Powering a Sustainable Future with DigitalCognizant
Utilities are starting to adopt digital technologies to eliminate slow processes, elevate customer experience and boost sustainability, according to our recent study.
AI in Media & Entertainment: Starting the Journey to ValueCognizant
Up to now, the global media & entertainment industry (M&E) has been lagging most other sectors in its adoption of artificial intelligence (AI). But our research shows that M&E companies are set to close the gap over the coming three years, as they ramp up their investments in AI and reap rising returns. The first steps? Getting a firm grip on data – the foundation of any successful AI strategy – and balancing technology spend with investments in AI skills.
Operations Workforce Management: A Data-Informed, Digital-First ApproachCognizant
As #WorkFromAnywhere becomes the rule rather than the exception, organizations face an important question: How can they increase their digital quotient to engage and enable a remote operations workforce to work collaboratively to deliver onclient requirements and contractual commitments?
Five Priorities for Quality Engineering When Taking Banking to the CloudCognizant
As banks move to cloud-based banking platforms for lower costs and greater agility, they must seamlessly integrate technologies and workflows while ensuring security, performance and an enhanced user experience. Here are five ways cloud-focused quality assurance helps banks maximize the benefits.
Getting Ahead With AI: How APAC Companies Replicate Success by Remaining FocusedCognizant
Changing market dynamics are propelling Asia-Pacific businesses to take a highly disciplined and focused approach to ensuring that their AI initiatives rapidly scale and quickly generate heightened business impact.
The Work Ahead in Intelligent Automation: Coping with Complexity in a Post-Pa...Cognizant
Intelligent automation continues to be a top driver of the future of work, according to our recent study. To reap the full advantages, businesses need to move from isolated to widespread deployment.
The Work Ahead in Intelligent Automation: Coping with Complexity in a Post-Pa...
Serialization: Driving Business Value Beyond Compliance
1. Serialization: Driving Business Value
Beyond Compliance
As serialization and track-and-trace capabilities go mainstream to
meet regulatory compliance mandates, pharmaceuticals companies
should simultaneously explore how these tools and techniques can
improve supply chain planning and operations, elevate patient and
doctor engagement, and increase sales and marketing effectiveness.
Executive Summary
High-value products, complex supply chains,
dependence on multiple organizations for dis-
tribution — all of these factors expose the
pharmaceuticals industry to threats such as coun-
terfeiting, theft and illegal diversions. In fact, the
Pharmaceutical Security Institute counts 2,177
incidents of counterfeiting worldwide in 2014
alone.1
To counter these threats and ensure the
integrity of the pharma supply chain, regulatory
initiatives are under way worldwide that mandate
serialization of medical products sold globally,
as well as the tracking and tracing of products
throughout the supply chain. The U.S., China,
South Korea, EU, Argentina, Brazil and other
regions of the world are all in different phases of
implementing serialization- and track-and-trace-
related regulations.
Whileregulatorycomplianceremainsatoppriority
for pharmaceuticals companies, the availability of
information about serialized products throughout
the supply chain provides a unique opportunity
for pharmas to take a data- and analytics-driven
approach to supply chain improvements that yield
greater efficiencies and effectiveness through
higher visibility and collaboration. Pharmas can
use serialization data in multiple ways, including
collecting inventory information across supply
nodes, monitoring the performance of execution
partners, cold chain monitoring and recall man-
agement; by doing so, they can bolster real-time
decision-making capabilities and increase supply
chain agility. Serialization data can considerably
strengthen fraud-prone process areas, such as
returns and chargebacks, as well as illegal diver-
sions, yielding direct savings for all supply chain
partners.
Serialization also provides pharmaceuticals
companies with a way to connect directly with
patients through patient-centric initiatives,
strengthen their patient services portfolio and
ensure brand loyalty. Patient authentication data,
for example, can be used to geographically map
customers and ensure adequate availability at
the nearest pharmacy. Serialization authentica-
tion can also help optimize refill management,
appointment bookings, patient education and dis-
ease management, among other services.
• Cognizant 20-20 Insights
cognizant 20-20 insights | september 2015
2. Pharmaceuticals companies can also use serial-
ization data to identify the relative performance
of various market segments to drive targeted
sales and marketing initiatives. They can then
analyze these interventions and programs and
further fine-tune them, thereby increasing sales
effectiveness and marketing spend efficiency.
When initiating serialization projects, phar-
maceuticals companies must look beyond
regulatory compliance to design the underlying
infrastructure, applications and processes that
drive value through new and supplemental busi-
ness capabilities.
This white paper explores the many ways that
new serialization capabilities can be utilized to
drive business value across corporate functions
and activities, thus enhancing the return on
investment (ROI) to achieve regulatory compli-
ance, globally.
The Serialization Context
The pharmaceuticals industry has faced chal-
lenges over the years to ensure the integrity of
products as they move across the supply chain,
from the manufacturing base to the patient.
These supply chains are also becoming increas-
ingly complex as pharmaceuticals companies
segue toward specialty products and focus on
lifestyle diseases. This has made it more difficult
for pharmas to devise secure
supply chain strategies to
close loopholes and avoid
losses.
According to the World Health
Organization (WHO), the
pharmaceuticals industry
loses nearly $40 billion each
year globally due to counter-
feiting.2
Product theft has
also increased; according to
Freight Watch International,
drugs account for about 15% of the estimated $8
billion to $12 billion in annual cargo theft.3
Counterfeiting and theft not only leads to losses
worth billions of dollars in potential sales oppor-
tunity, but it also increases patient safety risk.
Industry players also incur additional costs to
manage product recalls once counterfeit batches
have been identified. Lastly, negative publicity
related to counterfeiting and recalls have a direct
impact on brand image and future sales revenues.
Tamper-proof packaging and
3-D holograms were among
the earliest approaches
undertaken by the industry
and government regulators
to address counterfeiting.
However, these efforts are
now viewed as insufficient,
as such packaging has been
found to be vulnerable to manipulation. Recent
regulatory initiatives — such as product serial-
ization (i.e., assigning a unique identification
number to every saleable pharmaceuticals prod-
uct unit) and product tracking in the supply chain
(through pedigree documentation and/or regu-
latory reporting) — are under way to address
counterfeit drug concerns. Serialization and
track-and-trace regulations are already active
and enforced in numerous countries, such as
Turkey, Argentina and China. Additional coun-
tries, such as the U.S., Korea and Brazil, as well
as members of the EU, are in the process of
implementation or finalizing such regulations.
Within the next five years, approximately 65% of
the global market (by value, as of 2014 revenue
data) is expected to require serialization in the
supply chain.4
Driving Business Value from
Serialization
We have worked closely with major pharma-
ceuticals companies to explore and define
additional dimensions for creating business
value and increasing the ROI of their serialization
compliance-related investments. A serialization
compliance infrastructure enables two primary
capabilities — supply chain and consumption vis-
ibility — that can be leveraged for additional use
cases and as value drivers (see Figure 1, next
page).
Inventory Optimization
We recently conducted a benchmarking study5
to evaluate the current state of pharmaceuti-
cals supply chains as compared with those of
fast-moving consumer goods (FMCG) companies
(typically considered a best-in-class benchmark in
supply chain design, execution and performance
metrics). Our study found that, in general, the
pharmaceuticals industry is serving its market
as reliably as the FMCG industry, but at a much
higher service cost.
The first set of metrics compared supply chain
performance and reliability. Our analysis indicat-
cognizant 20-20 insights 2
According to the
World Health
Organization (WHO),
the pharmaceuticals
industry loses nearly
$40 billion each
year globally due to
counterfeiting.
Within the next five
years, approximately
65% of the global
market is expected to
require serialization
in the supply chain.
3. cognizant 20-20 insights 3
ed that the pharmaceuticals industry is, in general,
on par with the FMCG industry in on-time-in-full
(OTIF) and forecast accuracy (see Figure 2).
However, when we compared these two industries
on asset efficiency measures, we found that the
actual cost of attaining the same level of supply
chain reliability is much higher for the phar-
maecuticals industry (see Figure 3, next page).
Consumer goods supply chains, on average, com-
pleted their conversion of asset resources to
cash five times faster than pharmaceuticals. In
terms of actual inventory turnover, the consumer
goods industry was three times faster than the
pharmaceuticals industry. By focusing on this
area, pharmaceuticals companies could directly
improve their returns on equity.
By combining serialization with track-and-trace
supply chain event recording within databases
that are compliant with the Electronic Product
Code Information Services (EPCIS) standard,
industry players and their partners could real-
ize an additional supply chain platform to gauge
product movement, facilitate tighter collabo-
ration and/or enable more coordinated supply
chain planning. The same infrastructure deployed
for serialization track-and-trace regulatory
compliance can also serve a broader group of
stakeholders by increasing agility and responsive-
ness, as well as optimizing inventory levels and
costs across various supply chain levels or inven-
tory-stocking locations.
For supply chain planners, a fundamental busi-
ness goal is optimizing inventory across the
#
2
Inventory
Optimization
Addressing Illegal
Diversions
Supply Chain Visibility
Serialization &
Track-and-Trace
Infrastructure
Optimizing
Recalls &
Returns
Supply Chain
Operations
Monitoring
Consumption Visibility
Patient-Centric
Engagements
Brand Loyalty
Sales &
Marketing
Effectiveness
Demand
Forecast
Improvement
Serialization Dimensions to Drive Value Beyond Compliance
Figure 1
Figure 2
97.4%
97.5%
75%
72.3%
Forecast AccuracyOn-time-in-full
Pharmaceuticals Fast-Moving Consumer Goods
On measures of reliability,
both FMCG and pharma have
similar performance levels.
Measures of Reliability
4. supply chain while improving customer service.
The net inventory maintained at any customer
demand location to deliver superior customer
service must typically be balanced with the costs
of maintaining inventory at those locations (i.e.,
carrying, storage, security and obsolescence).
Stockouts not only result in lost opportunities
for revenue generation but
also may potentially impact
patient health and supply
chain partner performance.
According to a 2013 report,
Premier Healthcare Alliance
estimated that the annual
cost of drug shortages for U.S.
hospitals was $416 million.6
By implementing serializa-
tion technologies that enable
inventory visibility across the
supply chain, pharmaceuticals companies have
an additional source of near-real-time inventory
event data that can be used to optimize invento-
ry levels, shorten replenishment lead times and
avoid stockouts.
Supply Chain Operations Monitoring
The ability to increase supply chain visibility and
quickly respond to specific events can be a major
advantage in the competitive pharma market-
place. Externalization of supply chain activities
has increased dependence on service providers
in multiple areas, such as
logistics. An important first
step is for internal warehous-
ing and distribution teams
to develop performance
metrics and benchmarks
to manage external service
providers. To enable a truly
performance-driven supply
chain, pharmaceuticals com-
panies need mechanisms to
monitor the performance
indicators of different ful-
fillment teams and make
real-time decisions.
Pharmaceuticals companies are working with
their supply chain partners to establish and track
key performance indicators (KPIs) as part of their
supply chain contracts. But challenges remain to
effectively implement and monitor these metrics,
as well as gain dynamic visibility into changing
conditions in the supply chain. A serialization and
track-and-trace infrastructure can be used to cap-
ture and extract business transaction events (i.e.,
shipments, receipts and suspect products) and
provide data and event management feedback in
real time to support KPI monitoring, supply chain
dashboards, support inventory and cold chain
monitoring, and decision support.
With event data enabled by serialization and
track-and-trace, companies have additional
information they can use to monitor underlying
business processes more effectively and leverage
process improvement opportunities across orga-
nizational units and supply chain partners. They
can also effectively benchmark and improve ser-
vice delivery standards across the organization.
Cross-organizational collaboration provides vis-
ibility into the underlying processes and makes
execution-related information available to all rele-
vant stakeholders, thus allowing the entire supply
chain ecosystem to improve as one unit.
Optimizing Reverse Logistics:
Returns & Recalls
The pharmaceuticals industry incurs about $2 bil-
lion annually in costs associated with processing
returns, expirations and recalls, according to a
study by the Healthcare Distribution Management
Association (HDMA).7
A lack of accurate audit
trails and product authentication capabilities for
reverse logistics exposes the industry to fraud
and inefficiencies. Serialization and track-and-
cognizant 20-20 insights 4
Figure 3
10.6
2.2 2.5
Inventory Turnover
(Multiple of)
Cash Conversion Cycle
(No. of Days) x 10
Pharmaceuticals Fast-Moving Consumer Goods
7.6
FMCG converts resources to
cash five times faster and
turns inventory three times
faster than pharma.
Measures of Asset Efficiency
According to a 2013
report, Premier
Healthcare Alliance
estimated that the
annual cost of drug
shortages for U.S.
hospitals was $416
million.
With event data
enabled by
serialization and
track-and-trace,
companies have
additional information
they can use to more
effectively monitor
— and improve —
underlying business
processes.
5. cognizant 20-20 insights 5
trace capabilities fill these
gaps directly and can be
used to redesign reverse
logistics processes.
For example, supply chain
partners have many rea-
sons for initiating a return
of goods, such as expiry of
products, recalls, packag-
ing damages, etc. A product
authentication capability can greatly help various
supply chain partners to verify products when ini-
tiating returns.
Once authenticated, the physical product can be
shipped directly to the designated place for the
manufacturer to handle it, based on its status. The
ensuing supplemental information, and associat-
ed credit notes arising from the returns process,
can now follow throughout the entire supply
chain — all the way to the desired beneficiary,
based purely on the initial shipment details of the
serialized product. Doing so saves a significant
amount of time and money that would otherwise
have been spent on reverse logistics and verifi-
cation processes across the many entities in the
supply chain. An authentication process can help
companies identify and stop scenarios arising
from fraudulent activities or counterfeiting that
exploit loopholes in the returns/recall process.
Addressing Diversions and Chargeback
Reconciliation
Product diversion (from different countries or
consumer segments) is a real problem for phar-
maceuticals companies especially because of
arbitrage opportunities arising from country
or consumer segment pricing differentials. As
pharmaceuticals companies have adapted to
the market-driven realities of tiered pricing and
rebating across customer segments (managed
markets), they are increasingly challenged to
ensure that discounted consignments meant for
specific customers or geographies are consumed
by their intended targets rather than being divert-
ed elsewhere.
With serialization, companies can identify and
segregate the products intended for different
market and customer segments. Authentication
capabilities can help validate whether products
are consumed in the market or customer seg-
ment for which they were earmarked.
Similarly, pharmaceuticals companies have
responded to pricing pressures from group pur-
chasing organizations (GPOs), whose influence
on product volumes is significant enough to allow
for price discount contracts. The process of plac-
ing price discount contracts with wholesalers
that sell products to GPO members has result-
ed in the development of a chargeback process
under which the wholesaler claims the extra dis-
count provided to GPOs from pharmaceutical
companies.
From the pharmaceuticals company’s viewpoint,
the challenge of the chargeback reconciliation
process is that wholesaler sales data is usual-
ly unavailable to the manufacturer and must be
obtained from third parties. Sales reconciliation
typically takes place at the product/quantity/
customer level and not always at the lot level,
much less at the serialized lot level. Within the
U.S. market, a serialization track-and-trace infra-
structure and the associated serialized lot level
event (shipment) capture can provide new ways
for pharmaceuticals companies and wholesalers
to work together to streamline the reconciliation
processes, ensure chargeback payment accuracy,
save money and channel these savings into initia-
tives that allow for additional market incentives.
Driving Patient-Centric Engagements &
Brand Loyalty
Aided by advances in technology, healthcare is
undergoing a consumer-
ism revolution. Patients
are actively getting
involved in decision-mak-
ing processes that are
informed by a variety
of primary and second-
ary information sources.
Pharmaceuticals com-
panies have scaled up
their strategic capabili-
ties to engage patients
digitally across the disease lifecycle. Serialization
provides a very useful entry point and inter-
face for pharmaceuticals companies to capture
patient behavior and engage directly with them.
Authentication is a key benefit of patient-focused
functionality based on serialization infrastruc-
ture. Encouraging patients to authenticate the
products they buy can yield important informa-
tion that can be used in a variety of ways (see
Figure 4, next page).
The pharmaceuticals
industry incurs about
$2 billion annually in
costs associated with
processing returns,
expirations and recalls,
according to a study by
the HDMA.
Serialization provides
a very useful entry
point and interface
for pharmaceuticals
companies to capture
patient behavior
and engage directly
with them.
6. cognizant 20-20 insights 6
The ease of authentication will increase with the
rise in mobility. Of the 500 million smartphone
users worldwide, many will use a healthcare appli-
cation by the end of this year, and by 2018, half of
the more than 3.4 billion smartphone and tablet
users worldwide will have downloaded a mobile
health app.8
A pharmaceuticals product
authentication tool can be
added to a mobile application
via GPS tracking and location-
aware software to provide
geographical mapping of
patients and their purchase
points. This information can
be helpful in that ensuring an
appropriate supply of drugs is
maintained at relevant phar-
macies. Additionally, it can
provide unparalleled visibility
into real-time sales data that can be used for just-
in-time decision-making for avoiding stockouts
and planning alternate fulfillment mechanisms
when a pharmacy is dangerously out of stock on
a particular pharmaceutical, as well as for fine-
tuning forecasting models to accurately reflect
future product requirements.
Geographical information about patient popula-
tions that are consuming a given product can help
pharmas design disease awareness and manage-
ment programs for the patient community located
in those specific geographies. Pharmaceuticals
companies can actively collaborate with health-
care practitioners based on patient density and
help engender practitioner and patient trust,
fostering a sense of partnership and increasing
brand loyalty.
Pharmaceutical product authentication tools can
also be used to capture product SKUs purchased
by patients. When merged with prescription data,
authentication data can help track regimen com-
pliance, which remains an area of concern for all
healthcare practitioners. Such data can also help
pharmaceuticals companies more effectively pre-
dict when a patient will run out of a medication
and proactively send refill reminders. Relevant
entities on the supply side can also be notified
about the need for a particular product at a par-
ticular location as designated by the patient, thus
helping to transform the entire supply chain
into a demand-driven engine that will power the
emerging era of personalized medicine.
Point of purchase Geographical
mapping of patients
Authentication
Collaboration
with healthcare
providers (HCPs)
HCP
intervention
Patient
engagement
Product
fulfillment
Disease awareness
Disease management/
regimen adherence
Forum/community-
based services
Availability of
product refill at
point of purchase
Serialization Driving Patient Services
Figure 4
By the end of
this year, and by
2018, half of the
more than 3.4
billion smartphone
and tablet users
worldwide will
have downloaded a
mobile health app.
7. cognizant 20-20 insights 7
We believe that pharma-
ceuticals companies should
integrate serialization-relat-
ed capabilities within their
patient-connect-related digi-
tal initiatives. In general, the
industry is just starting to
develop mobile applications
related to disease and prod-
ucts. As a result, the time
is right to launch and pro-
mote authentication services
through remote platforms.
Pharma companies must
develop back-end business
processes that leverage data
collected through authenti-
cation workflows to build and
deliver personalized services
for patients and practitioners,
a move that would benefit the entire healthcare
ecosystem.
Improving Sales and Marketing Effectiveness
Pharmaceuticals companies spend enormous
amounts of money on educating healthcare
practitioners about the benefits of their brands
and promoting their products to this community.
While secondary information sources are avail-
able from various market research organizations
(MROs) that can be used to assess sales perfor-
mance across target segments and geographical
regions, serialization capabilities can also be used
to gather performance-related indicators to gen-
erate ground-level intelligence, thus leading to
increased sales and marketing effectiveness. In
fact, as of 2012 (the last year for which data is
available), $24 billion was spent by the pharma-
ceuticals industry on marketing to physicians.9
Geographical information on
patient populations can be
generated through patient
authentication data. The
overall effectiveness of the
sales force around brand pro-
motions can be quantitatively
evaluated, and specific coun-
ter-measures can be taken in
areas that are lagging. This
geographical data can be fur-
ther used to segment healthcare providers and
take appropriate measures (i.e., educating and
addressing practitioner concerns or extending
patient services). The outcome of these sales/
marketing measures can be measured through
increased authentication data and can loop back
to the decision model, fueling sales or marketing
activities.
Serialization can help marketing departments
address two challenges: identifying micro-mar-
kets that need intervention (where to spend)
and evaluating the effectiveness of intervention
(what to spend on); both are important dimen-
sions to assess ways of increasing marketing
spend effectiveness. Authentication data aris-
ing from serialization-related capabilities can
help with identifying market segments that need
intervention, enabling targeted initiatives to be
undertaken. Serialization provides an additional
tool to evaluate the effectiveness of intervention,
as any insight into authentication volume (posi-
tive, negative or no change) is a good measure
of the effect of intervention. These insights can
then be used to design better, more personalized
marketing programs.
Laying the Foundation
The business case is highly favorable for utilizing
serialization data to optimize existing processes
or develop new capabilities to address underlying
unmet need. But to successfully implement the
use cases, the pharmaceuticals industry needs to
address the foundational issues that will provide
a framework for all to benefit when investments
are made in developing serialization capabilities.
Data related to EPCIS events across supply chain
entities needs to be accessed, collated and ana-
lyzed for supply chain visibility-related initiatives.
This data may be available in a central reposi-
tory in countries like China, where regulatory
agencies are the sole custodian of data that is
recorded and exchanged between different enti-
ties in the pharmaceuticals supply chain. In other
countries, such as Turkey, data may be captured
in local repositories of different supply chain enti-
ties, such as CMOs, distributors, wholesalers and
pharmacies. The industry needs to work with
the regulatory agencies and their supply chain
partners to drive consensus and formulate data-
sharing agreements.
Another challenge that pharmas face is the
limited focus on aggregating vast amounts of
serialization data to enable business intelligence.
Niche product vendors are providing capabilities
that address regulatory compliance, while infra-
structure providers are addressing activities that
keep the business running as usual. Utilization of
technologies such as cloud-based big data analyt-
Relevant entities
on the supply side
can also be notified
about the need for a
particular product at
a particular location
as designated by the
patient, thus helping
to transform the
entire supply chain
into a demand-driven
engine that will
power the emerging
era of personalized
medicine.
Serialization can
help marketing
departments identify
micro-markets that
need intervention
and evaluate
the effectiveness of
intervention.
8. cognizant 20-20 insights 8
ics could provide some answers — if security and
cost-related concerns are adequately addressed.
Another area of deliberation is the lack of a
global/regional security model that defines the
guidelines for data access by various supply chain
partners. Visibility of serialization data is current-
ly limited by regulatory constraints imposed by
regional authorities. These regional regulatory
authorities dictate the standards for data access
and data exchange. A step in the right direction
was taken by member companies of Rx-360,10
an international pharmaceuticals supply chain
consortium, when they met to establish a global
traceability data exchange architecture in order
to facilitate interoperable data exchange — but
much more needs to be done.
Implementation Framework
Given the external dependencies that need to
be factored in, pharmaceuticals companies must
undertake a phased approach to implementing
serialization initiatives. Technical capabilities,
such as authentication services, geographical
mapping and EPCIS event capturing, can be lever-
aged across different use cases to ensure higher
ROI on those fronts. Figure 5 outlines consider-
ations that can help pharmaceuticals companies
advance their decision-making.
A Serialization Decision Matrix
Initiatives
Business
Value
Technology Requirements External Dependency Our Recommendations
Inventory
optimization
High • Access to EPCIS events
across supply chain
entities.
• Analytics platform to
collate and process
EPCIS event data
addressing different
business use cases,
such as reorder level,
stockout warnings,
inventory imbalances,
etc.
• Consensus among
supply chain partners
for sharing event
information.
• Adherence to common
technology standards,
such as EPCIS, across
organizations.
• Make inventory
optimization across
the supply chain
a shared business
goal for all supply
chain partners.
• Establish a high
degree of transpar-
ency and collabora-
tion, as both are
crucial for the
initiative to succeed.
Supply chain
operations
monitoring
Medium • Access to EPCIS events
across supply chain
entities.
• Analytics platform to
collate and process
EPCIS event data.
• Dashboard for real-time
monitoring of KPIs for
supply chain execution
vendors.
• Consensus among
supply chain partners
for sharing event
information.
• Adherence to
technology standards,
such as EPCIS, across
organizations.
• Agreement on KPIs
with supply chain
execution vendors.
• Establish common
benefits for supply
chain partners to
deploy reliable
and cost-effective
services with
real-time capabili-
ties to monitor and
take timely actions.
• Establish KPIs to
monitor, and include
these KPIs in vendor
contracts.
Optimizing recalls/
returns
High • Querying across
partners’ EPCIS reposi-
tories to track batch
movement.
• Authentication services
across the supply chain.
• Reporting and integra-
tion with ERP to enable
financial workflow.
• Access to EPCIS
repositories/data of
supply chain partners
for tracking batches.
• Agreement on new
authentication,
logistics and financial
processes.
• Establish common
benefits for supply
chain partners to
improve recalls/
returns efficiency
and prevent fraud.
• Critically evaluate
existing processes
and prepare the
business case.
Figure 5 | Continued on next page
9. 9cognizant 20-20 insights
Initiatives
Business
Value
Technology Requirements External Dependency Our Recommendation
Addressing illegal
diversions
Medium • Authentication services
across platforms (Web,
mobile application, SMS,
etc.).
• Analytics platform to
map consignments and
authentication requests.
• Workflow platform to
manage identified cases
and support investiga-
tion.
• Education of patients
on the usefulness of
authentication and
promotion of wider
adoption.
• Access to EPCIS
repositories/ event
data of pharmacies.
• Start leveraging
the sales forces to
authenticate and
geographically track
their consignments.
• Build authentica-
tion capabilities on
mobile applications
currently being
supported.
• Perform product
pricing policies
and portfolio
assessment to
identify suscep-
tible products and
prioritize efforts.
Driving
patient-centric
engagements
High • Authentication services
across platforms.
• Analytics platform for
geographical mapping.
• Patient applications to
enable different use
cases.
• Education of patients
on the usefulness of
authentication and
promotion of wider
adoption.
• Access to EPCIS
repositories/ event
data of pharmacies.
• Integrate authenti-
cation capabilities
with patient digital
services and inter-
action platforms.
Improving sales
and marketing
effectiveness
High • Authentication services
across platforms.
• Analytics platform for
geographical mapping.
• Integration with sales
force automation
and marketing spend
platforms.
• Education of patients
about the usefulness
of authentication and
promotion of wider
adoption.
• Access to EPCIS
repositories/ event
data of pharmacies.
• Translate estab-
lished benchmarks
to evaluate
marketing and
sales effectiveness
across territories to
authentication data.
• Develop a
framework to
integrate authen-
tication data with
other market-
sensing data to
increase demand
forecasting accuracy.
Figure 5
A Serialization Decision Matrix (from previous page)
As pharmaceuticals companies establish serializa-
tion capabilities, it is essential to establish future
use cases in which the serialization platform can
be used to enable additional business processes
and create value. Pharmaceuticals companies
should evaluate serialization solutions in light of
these future use cases to ensure scalability. We
suggest that pharmas proactively engage their
supply chain partners to drive consensus around
common business benefits that can be enabled
through serialization and undertake technology
proofs of concept to reinforce its virtues.
Looking Forward
The pharmaceuticals industry is projected to
invest a substantial amount of money and time
in the coming years to develop serialization capa-
bilities to ensure regulatory compliance. While
the immediate benefits around ensuring prod-
uct integrity and eliminating counterfeiting are
immense, there are compelling business scenari-
os in which serialization can be used to develop
new processes and capabilities or supplement
existing ones for tangible operational gains.
10. cognizant 20-20 insights 10
The pharmaceuticals industry needs to work on
many fronts, internal and external, to maximize
current and future ROI of serialization. As the
industry establishes a foundation for a serialized
supply chain, some of the imperatives include the
following:
• Engage with supply chain partners and
regulatory agencies to develop a framework
and standards for data interoperability and
accessibility. Plan joint initiatives with supply
chain partners to improve supply chain efficien-
cies benefiting the entire delivery ecosystem.
• Design a serialization architecture and
solution platforms, keeping in mind future
reusability and enablement of use cases to
improve supply chain visibility and consump-
tion visibility.
• Design, implement and integrate authen-
tication-related capabilities and workflows
with patient-centric digital initiatives to
gain consumption visibility. Undertake proofs
of concept to integrate consumption-related
data to fine-tune existing business processes.
Footnotes
1
The Pharmaceutical Security Institute (PSI) is a not-for-profit membership organization established in
2002 by the security directors from 14 major pharmaceutical companies. Today, PSI membership includes
28 pharmaceuticals manufacturers from many nations. For more information, see http://www.psi-inc.org/
index.cfm.
2
“Track & Trace in the Pharmaceutical Industry: Serialization Strategies and a Roadmap for
Procurement,” Procurement Leaders, March 10, 2015, http://www.procurementleaders.com/whitepapers/
online-directory-gep1/track--trace-in-the-pharmaceutical-industry-serialization-strategies-and-a-road-
map-for-procurement.
3
Katherin Eban, “Drug Theft Goes Big,” Fortune, March 31, 2011, http://fortune.com/2011/03/31/
drug-theft-goes-big/.
4
Results obtained from Cognizant’s internal secondary research after forecasting the growth of the
pharmaceuticals market in various countries in which serialization infrastructure, in some form, will be
implemented by 2018.
5
A Cognizant supply chain benchmarking study was conducted in 2014 to evaluate the current state of
pharmaceuticals supply chains, compared with the fast-moving consumer goods (FMCG) industry, using
publicly available information. The metrics reflect the average of four years, from 2010 to 2013.
6
“Report of the International Summit on Medicines Shortage,” Fédération Internationale Pharmaceutique
(FIP), June 2013, http://www.fip.org/files/fip/publications/FIP_Summit_on_Medicines_Shortage.pdf.
7
“Healthcare Distribution Management Association (HDMA) Offers Industry Report on Pharmaceutical
Returned Goods,” PR Newsire, March 22, 2002, http://www.prnewswire.com/news-releases/health-
care-distribution-management-association-hdma-offers-industry-report-on-pharmaceutical-returned-
goods-76593747.html.
8
“Mobile Medical Applications,” U.S. Food & Drug Administration, http://www.fda.gov/MedicalDevices/
ProductsandMedicalProcedures/ConnectedHealth/MobileMedicalApplications/ucm255978.htm.
9
2012 U.S. Pharmaceutical Company Promotion Spending, Cegedim Strategic Data, January 2013, http://
www.skainfo.com/health_care_market_reports/2012_promotional_spending.pdf.
10
“Pharma Supply Chain Companies Organize to Establish Global Traceability Data Exchange Architecture,”
RxTrace, Aug. 25, 2014, http://www.rxtrace.com/2014/08/pharma-supply-chain-companies-organize-to-
establish-global-traceability-data-exchange-architecture.html.